0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > LILRB4

LILRB4

Brief Information

Name:Leukocyte immunoglobulin-like receptor subfamily B member 4
Target Synonym:CD85k Antigen,Leukocyte immunoglobulin-like receptor 5,Immunoglobulin-like transcript 3,CD85k,CD85 antigen-like family member K,LIR-5,Monocyte inhibitory receptor HM18,ILT-3,Leucocyte Ig-Like Receptor B4,ILT3,LIR5,Leukocyte Immunoglobulin-Like Receptor, Subfamily B (With TM And ITIM Domains), Member 4,HM18,Leukocyte Immunoglobulin Like Receptor B4
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Cat . Non Espèces Description du produit Structure Pureté Caractéristique
CDK-M82E3 Mouse Biotinylated Mouse LILRB4 / CD85k / ILT3 Protein, His,Avitag™ (MALS verified)
CDK-M82E3-structure
CDK-M82E3-sds
CHEK-ATP088 Human HEK293/Human LILRB4 Stable Cell Line
SCCHO-ATP087 Human CHO/Human LILRB4 Stable Cell Line Development Service
LI4-H82F6 Human Biotinylated Human LILRB4 / CD85k / ILT3 Protein, Fc,Avitag™ (MALS verified)
LI4-H82F6-structure
LI4-H82F6-sds
LI4-H5257 Human Human LILRB4 / CD85k / ILT3 Protein, Mouse IgG2a Fc Tag (MALS verified)
LI4-H5257-structure
LI4-H5257-sds
LI4-H5256 Human Human LILRB4 / CD85k / ILT3 Protein, Fc Tag (MALS verified)
LI4-H5256-structure
LI4-H5256-sds
LI4-HF254 Human FITC-Labeled Human LILRB4 / CD85k / ILT3 Protein, Fc Tag
LI4-HF254-structure
LI4-HF254-sds
LI4-H82E4 Human Biotinylated Human LILRB4 / CD85k / ILT3 Protein, His,Avitag™ (MALS verified)
LI4-H82E4-structure
LI4-H82E4-sds
LI4-HF2H3 Human FITC-Labeled Human LILRB4 / CD85k / ILT3 Protein, His Tag
LI4-HF2H3-structure
LI4-HF2H3-sds
LI4-H52H7 Human Human LILRB4 / CD85k / ILT3 Protein, His Tag (MALS verified)
LI4-H52H7-structure
LI4-H52H7-sds
LI4-C5250 Cynomolgus Cynomolgus LILRB4 / CD85k / ILT3 Protein, Mouse IgG2a Fc Tag
LI4-C5250-structure
LI4-C5250-sds
CDK-M5229 Mouse Mouse LILRB4 / CD85k / ILT3 Protein, His Tag (MALS verified)
CDK-M5229-structure
CDK-M5229-sds
CDK-C5227 Cynomolgus Cynomolgus LILRB4 / CD85k / ILT3 Protein, His Tag (MALS verified)
CDK-C5227-structure
CDK-C5227-sds
CDK-C5258 Cynomolgus Cynomolgus LILRB4 / CD85k / ILT3 Protein, Fc Tag
CDK-C5258-structure
CDK-C5258-sds
ACRO Quality

Part of Bioactivity data

LI4-H52H7-SPR
 LILRB4 SPR

Human ANGPTL7, His Tag immobilized on CM5 Chip can bind Human LILRB4, His Tag (Cat. No. LI4-H52H7) with an affinity constant of 4.67 μM as determined in a SPR assay (Biacore T200) (Routinely tested).

LI4-H5257-ELISA
 LILRB4 ELISA

Immobilized Human LILRB4, Mouse IgG2a Fc Tag (Cat. No. LI4-H5257) at 1 μg/mL (100 μL/well) can bind Anti-LILRB4 Antibody, Human IgG1 with a linear range of 0.1-2 ng/mL (QC tested).

Synonym Name

LILRB4,ILT3,LIR5,CD85K,HM18

Background

Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4) is also known as CD85 antigen-like family member K (CD85K), Immunoglobulin-like transcript 3 (ILT-3), Leukocyte immunoglobulin-like receptor 5 (LIR-5), Monocyte inhibitory receptor HM18, which belongs to the leukocyte immunoglobulin-like receptor (LIR) family. LILRB4 / CD85K contains 2 Ig-like C2-type (immunoglobulin-like) domains. CD85K is detected in monocytes, macrophages, dendritic cells, lung, natural killer cells and B-cells. LILRB4 / CD85K is receptor for class I MHC antigens. CD85K recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles, involved in the down-regulation of the immune response and the development of tolerance. LILRB4 interferes with TNFRSF5-signaling and NF-kappa-B up-regulation and inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
MK-0482 MK-0482 Phase 2 Clinical Merck Sharp & Dohme Corp Solid tumours; Leukemia, Myelomonocytic, Chronic; Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung Details
IO-202 IO-202 Phase 1 Clinical Yiming Biomedical Technology (Hangzhou) Co Ltd Solid tumours; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute Details
YTS-104 LILRB4 STAR-T; YTS-104 Phase 1 Clinical Beijing Qingyi Taike Pharmaceutical Technology Co Ltd Leukemia, Myeloid; Leukemia, Myeloid, Acute Details
BND-35 BND-35; BND35 Phase 1 Clinical Biond Biologics Ltd Solid tumours; Neoplasms Details
NGM-831 NGM-831 Phase 1 Clinical Ngm Biopharmaceuticals Inc Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Mesothelioma; Cholangiocarcinoma; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
anti-ILT3 CAR-T Therapy(Carbiogene) Phase 1 Clinical Carbiogene Therapeutics Co Ltd Leukemia, Myeloid, Acute Details
MK-0482 MK-0482 Phase 2 Clinical Merck Sharp & Dohme Corp Solid tumours; Leukemia, Myelomonocytic, Chronic; Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung Details
IO-202 IO-202 Phase 1 Clinical Yiming Biomedical Technology (Hangzhou) Co Ltd Solid tumours; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute Details
YTS-104 LILRB4 STAR-T; YTS-104 Phase 1 Clinical Beijing Qingyi Taike Pharmaceutical Technology Co Ltd Leukemia, Myeloid; Leukemia, Myeloid, Acute Details
BND-35 BND-35; BND35 Phase 1 Clinical Biond Biologics Ltd Solid tumours; Neoplasms Details
NGM-831 NGM-831 Phase 1 Clinical Ngm Biopharmaceuticals Inc Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Mesothelioma; Cholangiocarcinoma; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
anti-ILT3 CAR-T Therapy(Carbiogene) Phase 1 Clinical Carbiogene Therapeutics Co Ltd Leukemia, Myeloid, Acute Details

This web search service is supported by Google Inc.

totop

Laisser un message